This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LRRK2 Program (Denali/Genentech)

Denali Therapeutics Inc.

Drug Names(s): LRRK2 Parkinson's Program

Description: Denali and Genentech are developing LRRK2 inhibitors for the treatment of Parkinson's disease.

Deal Structure: Denali and Genentech
In August 2016, Denali disclosed a licensing agreement with Genentech, a member of the Roche group, for exclusive global rights to develop and commercialize LRRK2 inhibitors for the treatment of Parkinson's disease.

Partners: Roche Holding AG


LRRK2 Program (Denali/Genentech) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug